Name | Number of supported studies | Average coverage | |
---|---|---|---|
endothelial cell | 14 studies | 29% ± 14% | |
oligodendrocyte | 12 studies | 37% ± 15% | |
astrocyte | 10 studies | 33% ± 14% | |
microglial cell | 9 studies | 26% ± 10% | |
adipocyte | 9 studies | 27% ± 7% | |
oligodendrocyte precursor cell | 8 studies | 34% ± 15% | |
glutamatergic neuron | 6 studies | 48% ± 23% | |
macrophage | 6 studies | 33% ± 7% | |
epithelial cell | 6 studies | 32% ± 14% | |
fibroblast | 6 studies | 23% ± 4% | |
GABAergic neuron | 6 studies | 45% ± 19% | |
interneuron | 5 studies | 43% ± 21% | |
neuron | 5 studies | 44% ± 20% | |
pericyte | 5 studies | 32% ± 13% | |
ciliated cell | 5 studies | 21% ± 5% | |
endothelial cell of lymphatic vessel | 5 studies | 26% ± 5% | |
type I pneumocyte | 5 studies | 23% ± 6% | |
cardiac muscle cell | 4 studies | 24% ± 1% | |
retinal rod cell | 4 studies | 23% ± 5% | |
monocyte | 4 studies | 22% ± 5% | |
club cell | 4 studies | 20% ± 6% | |
smooth muscle cell | 4 studies | 22% ± 4% | |
type II pneumocyte | 4 studies | 22% ± 5% | |
granule cell | 3 studies | 24% ± 3% | |
myeloid cell | 3 studies | 22% ± 5% | |
hepatocyte | 3 studies | 30% ± 18% | |
dendritic cell | 3 studies | 18% ± 2% | |
abnormal cell | 3 studies | 29% ± 17% | |
T cell | 3 studies | 16% ± 1% | |
alveolar macrophage | 3 studies | 25% ± 8% | |
lymphocyte | 3 studies | 23% ± 4% | |
transit amplifying cell | 3 studies | 29% ± 16% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 4026.06 | 1445 / 1445 | 100% | 41.23 | 183 / 183 |
stomach | 100% | 3222.90 | 359 / 359 | 100% | 36.37 | 285 / 286 |
intestine | 100% | 4432.39 | 966 / 966 | 100% | 30.83 | 525 / 527 |
prostate | 100% | 3719.47 | 245 / 245 | 99% | 20.82 | 499 / 502 |
skin | 100% | 4824.51 | 1809 / 1809 | 99% | 24.01 | 469 / 472 |
ovary | 100% | 3567.99 | 180 / 180 | 99% | 26.45 | 427 / 430 |
bladder | 100% | 3907.10 | 21 / 21 | 99% | 24.98 | 500 / 504 |
breast | 100% | 3716.33 | 459 / 459 | 99% | 30.73 | 1109 / 1118 |
brain | 100% | 3567.90 | 2630 / 2642 | 99% | 26.46 | 700 / 705 |
thymus | 100% | 4592.34 | 653 / 653 | 99% | 20.26 | 597 / 605 |
lung | 100% | 3634.65 | 578 / 578 | 99% | 25.42 | 1138 / 1155 |
uterus | 100% | 4057.60 | 170 / 170 | 98% | 23.38 | 450 / 459 |
kidney | 100% | 3233.54 | 89 / 89 | 98% | 16.54 | 883 / 901 |
pancreas | 99% | 1951.74 | 326 / 328 | 98% | 19.08 | 175 / 178 |
adrenal gland | 100% | 3347.94 | 258 / 258 | 97% | 15.70 | 222 / 230 |
liver | 100% | 1546.46 | 226 / 226 | 78% | 9.46 | 318 / 406 |
adipose | 100% | 3702.66 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 3665.36 | 1335 / 1335 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 14.59 | 80 / 80 |
muscle | 100% | 2699.90 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 3047.59 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 32.16 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 12.19 | 1 / 1 |
heart | 97% | 2158.04 | 838 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 94% | 2116.34 | 875 / 929 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 86% | 11.05 | 25 / 29 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007507 | Biological process | heart development |
GO_0006974 | Biological process | DNA damage response |
GO_0009725 | Biological process | response to hormone |
GO_0045893 | Biological process | positive regulation of DNA-templated transcription |
GO_0030099 | Biological process | myeloid cell differentiation |
GO_0007420 | Biological process | brain development |
GO_0006352 | Biological process | DNA-templated transcription initiation |
GO_0045944 | Biological process | positive regulation of transcription by RNA polymerase II |
GO_0035097 | Cellular component | histone methyltransferase complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0044666 | Cellular component | MLL3/4 complex |
GO_0043231 | Cellular component | intracellular membrane-bounded organelle |
GO_0005667 | Cellular component | transcription regulator complex |
GO_0005634 | Cellular component | nucleus |
GO_0046966 | Molecular function | nuclear thyroid hormone receptor binding |
GO_0019899 | Molecular function | enzyme binding |
GO_0003682 | Molecular function | chromatin binding |
GO_0030331 | Molecular function | nuclear estrogen receptor binding |
GO_0046965 | Molecular function | nuclear retinoid X receptor binding |
GO_0003713 | Molecular function | transcription coactivator activity |
GO_0030374 | Molecular function | nuclear receptor coactivator activity |
GO_0005515 | Molecular function | protein binding |
Gene name | NCOA6 |
Protein name | Nuclear receptor coactivator 6 Nuclear receptor coactivator-6 gamma Nuclear receptor coactivator 6 (Nuclear receptor coactivator-6 delta) Nuclear receptor coactivator 6 (Nuclear receptor coactivator-6 beta) Nuclear receptor coactivator 6 (Activating signal cointegrator 2) (ASC-2) (Amplified in breast cancer protein 3) (Cancer-amplified transcriptional coactivator ASC-2) (Nuclear receptor coactivator RAP250) (NRC RAP250) (Nuclear receptor-activating protein, 250 kDa) (Peroxisome proliferator-activated receptor-interacting protein) (PPAR-interacting protein) (PRIP) (Thyroid hormone receptor-binding protein) NCOA6 protein |
Synonyms | AIB3 TRBP RAP250 KIAA0181 |
Description | FUNCTION: Nuclear receptor coactivator that directly binds nuclear receptors and stimulates the transcriptional activities in a hormone-dependent fashion. Coactivates expression in an agonist- and AF2-dependent manner. Involved in the coactivation of different nuclear receptors, such as for steroids (GR and ERs), retinoids (RARs and RXRs), thyroid hormone (TRs), vitamin D3 (VDR) and prostanoids (PPARs). Probably functions as a general coactivator, rather than just a nuclear receptor coactivator. May also be involved in the coactivation of the NF-kappa-B pathway. May coactivate expression via a remodeling of chromatin and its interaction with histone acetyltransferase proteins. |
Accessions | Q1RMZ3 ENST00000359003.7 Q14686 F6M2K2 ENST00000616167.1 F6M2K3 ENST00000374796.6 A0A0D9SFT8 ENST00000628752.2 F6M2K4 ENST00000612493.4 |